Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Filamon LTD
PMV Pharmaceuticals, Inc
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
M.D. Anderson Cancer Center
Xencor, Inc.
Memorial Sloan Kettering Cancer Center
ViroMissile, Inc.
University of Florida
Tizona Therapeutics, Inc
Essen Biotech
Clasp Therapeutics, Inc.
OHSU Knight Cancer Institute
Baylor College of Medicine
University of Colorado, Denver
Centre Paul Strauss
Roswell Park Cancer Institute
Daiichi Sankyo
Boehringer Ingelheim
University of Michigan Rogel Cancer Center
Kidney Cancer Research Bureau
HealthPartners Institute
Second Life Therapeutics
University of Kansas Medical Center
NRG Oncology
Medical College of Wisconsin
Fred Hutchinson Cancer Center
Novartis
Var2 Pharmaceuticals
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Complement Theory Inc.
City of Hope Medical Center
University Health Network, Toronto
UNICANCER
NantCell, Inc.
Hospices Civils de Lyon
AstraZeneca
Dana-Farber Cancer Institute
IDEAYA Biosciences
Tempus AI
Virginia Commonwealth University
University of Calgary
Memorial Sloan Kettering Cancer Center